Up-regulation of the fibroblast growth factor 8 subfamily in human hepatocellular carcinoma for cell survival and neoangiogenesis

Hepatology

Volumn 53, Issue 3, 2011, Pages 854-864

  Gauglhofer, Christine ^a   Sagmeister, Sandra ^a   Schrottmaier, Waltraud ^a   Fischer, Carina ^a   Rodgarkia Dara, Chantal ^a   Mohr, Thomas ^a   Stättner, Stefan ^b   Bichler, Christoph ^c   Kandioler, Daniela ^c   Wrba, Fritz ^c   Schulte Hermann, Rolf ^a   Holzmann, Klaus ^a   Grusch, Michael ^a   Marian, Brigitte ^a   Berger, Walter ^a   Grasl Kraupp, Bettina ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b Social Medical Center South   (Austria)

^c MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

AGAR; DEFEROXAMINE MESYLATE; FIBROBLAST GROWTH FACTOR; FIBROBLAST GROWTH FACTOR 17; FIBROBLAST GROWTH FACTOR 18; FIBROBLAST GROWTH FACTOR 8; FIBROBLAST GROWTH FACTOR RECEPTOR 2; FIBROBLAST GROWTH FACTOR RECEPTOR 3; FIBROBLAST GROWTH FACTOR RECEPTOR 4; MITOGEN ACTIVATED PROTEIN KINASE 3; PROTEIN S6; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ANGIOGENESIS; APOPTOSIS; ARTICLE; AUTOCRINE EFFECT; CANCER GROWTH; CELL DENSITY; CELL MEMBRANE POTENTIAL; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; DOWN REGULATION; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; HUMAN TISSUE; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; MESENCHYME CELL; MYOFIBROBLAST; NEOANGIOGENESIS; PARACRINE SIGNALING; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; TUMOR MICROENVIRONMENT; UPREGULATION; VASCULARIZATION;

ANIMALS; ANOXIA; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CELL SURVIVAL; FIBROBLAST GROWTH FACTOR 8; FIBROBLAST GROWTH FACTORS; HUMANS; LIVER NEOPLASMS; MITOGEN-ACTIVATED PROTEIN KINASES; NEOVASCULARIZATION, PATHOLOGIC; PROTO-ONCOGENE PROTEINS C-AKT; RATS; RECEPTORS, FIBROBLAST GROWTH FACTOR; TUMOR MICROENVIRONMENT; UP-REGULATION;

EID: 79952212865     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.24099     Document Type: Article

References (32)

1. El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 2007; 132: 2557-2576.
2. Llovet JM, Bruix J. Molecular targeted therapies in hepatocellular carcinoma. HEPATOLOGY 2008; 48: 1312-1327.
3. Berasain C, Castillo J, Perugorria MJ, Latasa MU, Prieto J, Avila MA. Inflammation and liver cancer: new molecular links. Ann N Y Acad Sci 2009; 1155: 206-221.
4. Grasl-Kraupp B, Luebeck G, Wagner A, Löw-Baselli A, de Gunst M, Waldhör T, et al. Quantitative analysis of tumor initiation in rat liver: role of cell replication and cell death (apoptosis). Carcinogenesis 2000; 21: 1411-1421.
5. Raidl M, Pirker C, Schulte-Hermann R, Aubele M, Kandioler-Eckersberger D, Micksche M, et al. Multiple chromosomal abnormalities in human liver (pre)neoplasia. J Hepatol 2004; 40: 660-668.
6. Drucker C, Parzefall W, Teufelhofer O, Grusch M, Ellinger A, Schulte-Hermann R, et al. Non-parenchymal liver cells support the growth advantage in the first stages of hepatocarcinogenesis. Carcinogenesis 2006; 27: 152-161.
7. Sagmeister S, Drucker C, Losert A, Grusch M, Daryabeigi A, Parzefall W, et al. HB-EGF is a paracrine growth stimulator for early tumor prestages in inflammation-driven hepatocarcinogenesis. J Hepatol 2008; 49: 955-964.
8. Macheiner D, Gauglhofer C, Rodgarkia-Dara C, Grusch M, Brachner A, Bichler C, et al. NORE1B is a putative tumor suppressor in hepatocarcinogenesis and may act via RASSF1A. Cancer Res 2009; 69: 235-242.
9. Imbeaud S, Ladeiro Y, Zucman-Rossi J. Identification of novel oncogenes and tumor suppressors in hepatocellular carcinoma. Semin Liver Dis 2010; 30: 75-86.
10. Clevers H. Axin and hepatocellular carcinomas. Nat Genet 2000; 24: 206-208.
11. Tlsty TD, Coussens LM. Tumor stroma and regulation of cancer development. Ann Rev Pathol 2006; 1: 119-150.
12. Sagmeister S, Eisenbauer M, Pirker C, Mohr T, Holzmann K, Zwickl H, et al. New cellular tools reveal complex epithelial mesenchymal interactions in hepatocarcinogenesis. Br J Cancer 2008; 99: 151-159.
13. Breuhahn K, Longerich T, Schirmacher P. Dysregulation of growth factor signaling in human hepatocellular carcinoma. Oncogene 2006; 25: 3787-3800.
14. Turner N, Grose R. Fibroblast growth factor signalling: from development to cancer. Nat Rev Cancer 2010; 10: 116-129.
15. Allerstorfer S, Sonvilla G, Fischer H, Spiegl-Kreinecker S, Gauglhofer C, Setinek U, et al. FGF5 as an oncogenic factor in human glioblastoma multiforme: autocrine and paracrine activities. Oncogene 2008; 27: 4180-4190.
16. Sonvilla G, Allerstorfer S, Stättner S, Karner J, Klimpfinger M, Fischer H, et al. FGF18 in colorectal tumour cells: autocrine and paracrine effects. Carcinogenesis 2008; 29: 15-24.
17. Francavilla C, Loeffler S, Piccini D, Kren A, Christofori G, Cavallaro U. Neural cell adhesion molecule regulates the cellular response to fibroblast growth factor. J Cell Sci 2007; 120: 4388-4394.
18. Imura S, Miyake H, Izumi K, Tashiro S, Uehara H. Correlation of vascular endothelial cell proliferation with microvessel density and expression of vascular endothelial growth factor and basic fibroblast growth factor in hepatocellular carcinoma. J Med Invest 2004; 51: 202-209.
19. Zhang X, Ibrahimi OA, Olsen SK, Umemori H, Mohammadi M, Ornitz DM. Receptor specificity of the fibroblast growth factor family. The complete mammalian FGF family. J Biol Chem 2006; 281: 15694-15700.
20. Mattila MM, Härkönen PL. Role of fibroblast growth factor 8 in growth and progression of hormonal cancer. Cytokine Growth Factor Rev 2007; 18: 257-266.
21. Heer R, Douglas D, Mathers ME, Robson CN, Leung HY. Fibroblast growth factor 17 is over-expressed in human prostate cancer. J Pathol 2004; 204: 578-586.
22. Tchagang AB, Tewfik AH, DeRycke MS, Skubitz KM, Skubitz AP. Early detection of ovarian cancer using group biomarkers. Mol Cancer Ther 2008; 7: 27-37.
23. Ishibe T, Nakayama T, Okamoto T, Aoyama T, Nishijo K, Shibata KR, et al. Disruption of fibroblast growth factor signal pathway inhibits the growth of synovial sarcomas: potential application of signal inhibitors to molecular target therapy. Clin Cancer Res 2005; 11: 2702-2712.
24. Antoine M, Wirz W, Tag CG, Gressner AM, Wycislo M, Müller R, et al. Fibroblast growth factor 16 and 18 are expressed in human cardiovascular tissues and induce on endothelial cells migration but not proliferation. Biochem Biophys Res Commun 2006; 346: 224-233.
25. Hu MC, Qiu WR, Wang YP, Hill D, Ring BD, Scully S, et al. FGF-18, a novel member of the fibroblast growth factor family, stimulates hepatic and intestinal proliferation. Mol Cell Biol 1998; 18: 6063-6074.
26. Alessandri G, Chirivi RG, Castellani P, Nicoló G, Giavazzi R, Zardi L. Isolation and characterization of human tumor-derived capillary endothelial cells: role of oncofetal fibronectin. Lab Invest 1998; 78: 127-128.
27. Reinhold MI, Naski MC. Direct interactions of runx2 and canonical wnt signaling induce FGF18. J Biol Chem 2007; 282: 3653-3663.
28. Templeton DM, Liu Y. Genetic regulation of cell function in response to iron overload or chelation. Biochim Biophys Acta 2003; 1619: 113-124.
29. Liao Y, Hung MC. Physiological regulation of Akt activity and stability. Am J Transl Res 2010; 2: 19-42.
30. Kim EK, Choi EJ. Pathological roles of MAPK signaling pathways in human diseases. Biochim Biophys Acta 2010; 1802: 396-405.
31. Beenken A, Mohammadi M. The FGF family: biology, pathophysiology and therapy. Nat Rev Drug Discov 2009; 8: 235-253.
32. Smedsrød B, Le Couteur D, Ikejima K, Jaeschke H, Kawada N, Naito M, et al. Hepatic sinusoidal cells in health and disease. Liver Int 2009; 29: 490-501.